Statins are lipid-lowering agents that possess immunomodulatory properties that could be in part mediated by the down-regulation of the toll-like receptors (TLRs), involved in pathogens recognition by immune cells [8, 9]. Among TLRs, TLR-2 is likely to sense the immune response to S. aureus . Statins could be protective in pneumonia according to some concordant clinical data [11, 12]. In addition, experimental studies have demonstrated a lung-protective effect through VILI attenuation [13, 14]. Outcomes in VAP patients were improved by prior treatment with statins . This remains however a controversial issue .